Mitokinin
Dr. Crawford goal is Managing Director of Mission Bay Capital. He has overseen the investment in 40 companies, 6 of which have already enjoyed successful exits (Calithera, iPierian, Redwood Biosciences, True North, Zephyrus, and Cell Design Labs). In additional to Mitokinin, he is also a board member of Avexegen, Circle Pharma, Epiodyne, Graphwear, Invenio, Magnamosis, Magnap, SiteOne (observer), and Tangible Sciences.
Dr. Crawford created and continues to manages MBC BioLabs, a state-of-the-art co-working laboratory program in San Francisco. In its first 4 years, MBC BioLabs helped launch 104 companies that have raised over $1.76 billion. This incubator program reflects Doug’s passion for startups and his eagerness to help entrepreneurs overcome challenges.
Dr. Crawford received his PhD in biochemistry from UCSF.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.